ImmunoCellular
ImmunoCellular Therapeutics, Ltd. (Form: SC 13G, Received: 07/19/2017 12:08:45)

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 
 

SCHEDULE 13G

 

 
 
Under the Securities Exchange Act of 1934
 
(Amendment No.   )*
 

ImmunoCellular Therapeutics, Ltd.

(Name of Issuer)
 

Common Stock, $0.0001 par value

(Title of Class of Securities)
 

452536204

(CUSIP Number)
 

July 17, 2017

(Date of event which requires filing of this statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
 
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 9 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 452536204

13G

Page 2  of 9 Pages

 

1

NAMES OF REPORTING PERSONS

Empery Asset Management, LP

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ¨

(b)  ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

 

6

SHARED VOTING POWER

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.99% (See Item 4)*

12

TYPE OF REPORTING PERSON

PN

         

 

* As more fully described in Item 4, the shares of Preferred Stock are subject to a 9.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

 

CUSIP No. 452536204

13G

Page 3  of 9 Pages

 

1

NAMES OF REPORTING PERSONS

Ryan M. Lane

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ¨

(b)  ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

 

6

SHARED VOTING POWER

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.99% (See Item 4)*

12

TYPE OF REPORTING PERSON

IN

         

 

* As more fully described in Item 4, the shares of Preferred Stock are subject to a 9.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

 

CUSIP No. 452536204

13G

Page 4  of 9 Pages

 

1

NAMES OF REPORTING PERSONS

Martin D. Hoe

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ¨

(b)  ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

 

6

SHARED VOTING POWER

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

7

SOLE DISPOSITIVE POWER

 

8

SHARED DISPOSITIVE POWER

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

442,623 shares of Common Stock issuable upon conversion of Preferred Stock (See Item 4)*

796,721 shares of Common Stock issuable upon conversion of Preferred Stock issuable upon exercise of Warrants to Purchase Preferred Stock (See Item 4)*

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.99% (See Item 4)*

12

TYPE OF REPORTING PERSON

IN

         

 

* As more fully described in Item 4, the shares of Preferred Stock are subject to a 9.99% blocker, and the percentage set forth in row (11) gives effect to such blockers. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (6), (8) and (9).

 

CUSIP No. 452536204

13G

Page 5  of 9 Pages

 

Item 1(a). NAME OF ISSUER:
   
  The name of the issuer is ImmunoCellular Therapeutics, Ltd. (the " Company ").
Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
   
  The Company's principal executive offices are located at 23622 Calabasas Road, Suite 300, Calabasas, CA 91302.
Item 2(a). NAME OF PERSON FILING:

 

 

This statement is filed by the entities and persons listed below, who are collectively referred to herein as " Reporting Persons ," with respect to the shares of Common Stock (as defined in Item 2(d) below) of the Company:

 

Investment Manager

 

(i)       Empery Asset Management, LP (the " Investment Manager "), with respect to the shares of Common Stock held by, and underlying the Reported Preferred Stock (as defined below) held by, the funds to which the Investment Manager serves as investment manager (the " Empery Funds ").

 

Reporting Individuals

 

(ii)       Mr. Ryan M. Lane (" Mr. Lane "), with respect to the shares of Common Stock held by, and underlying the Reported Preferred Stock held by, the Empery Funds.

 

(iii)       Mr. Martin D. Hoe (" Mr. Hoe "), with respect to the shares of Common Stock held by, and underlying the Reported Preferred Stock held by, the Empery Funds.

 

The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the " Reporting Individuals ") is a Managing Member of Empery AM GP, LLC (the " General Partner "), the general partner of the Investment Manager.

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

 

The address of the business office of each of the Reporting Persons is:

 

1 Rockefeller Plaza, Suite 1205

New York, New York 10020

 

Item 2(c). CITIZENSHIP:

 

  Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

 

Item 2(d). TITLE OF CLASS OF SECURITIES:
   
  Common Stock, $0.0001 par value (the " Common Stock ")

 

 

CUSIP No. 452536204

13G

Page 6  of 9 Pages

 

Item 2(e). CUSIP NUMBER:
   
  452536204

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

  (a) ¨ Broker or dealer registered under Section 15 of the Act,
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
  (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
  (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
  (e) ¨ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
  (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
  (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
  (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
  (i) ¨ Church Plan that is excluded from the definition of an investment company under Section
3(c)(14) of the Investment Company Act of 1940,
  (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

specify the type of institution: ______________________________________

 

Item 4. OWNERSHIP .

 

   

The information as of the date of the event which requires filing of this statement required by Items
4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 3,449,075 shares of Common Stock issued and outstanding as of March 31, 2017, as represented in Amendment #4 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 13, 2017 and assumes the exercise in full of the Warrants to purchase Preferred Stock and the conversion in full, subject to the Blockers (as defined below) of the shares of Preferred Stock owned and issuable upon exercise of such warrants (the “ Reported Preferred Stock ”).

 

 

CUSIP No. 452536204

13G

Page 7  of 9 Pages

 

    Pursuant to the terms of the Certificate of Designations governing the terms of the Reported Preferred Stock, the Reporting Persons cannot convert the Reported Preferred Stock to the extent the Reporting Persons would beneficially own, after any such conversion, more than 9.99% of the outstanding shares of Common Stock (the " Blockers "), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.  Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to convert all of the Reported Preferred Stock due to the Blockers.
     
    The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Preferred Stock (subject to the Blockers) held by, the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Preferred Stock (subject to the Blockers) held by, the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
  Not applicable.

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
  See Item 2(a) above.

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
  Not applicable.

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
  Not applicable.

 

Item 9. NOTICE OF DISSOLUTION OF GROUP.
  Not applicable.

 

Item 10. CERTIFICATION.

 

  Each of the Reporting Persons hereby makes the following certification:
   
  By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

CUSIP No. 452536204

13G

Page 8  of 9 Pages

 

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: July 19, 2017

   
   
  EMPERY ASSET MANAGEMENT, LP
  By: EMPERY AM GP, LLC, its General Partner
   
  By: _ /s/ Ryan M. Lane ___________________
  Name:  Ryan M. Lane
  Title:  Managing Member
   
  _ /s/ Ryan M. Lane ______________________
  Ryan M. Lane
   
  _ /s/ Martin D. Hoe ______________________
  Martin D. Hoe

 

 

 

 

CUSIP No. 452536204

13G

Page 9  of 9 Pages

 

EXHIBIT 1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: July 19, 2017

 

   
  EMPERY ASSET MANAGEMENT, LP
  By: EMPERY AM GP, LLC, its General Partner
   
  By: _ /s/ Ryan M. Lane ___________________
  Name:  Ryan M. Lane
  Title:  Managing Member
   
  _ /s/ Ryan M. Lane ______________________
  Ryan M. Lane
   
  _ /s/ Martin D. Hoe ______________________
  Martin D. Hoe